Equity Profile

IMNM

Immunome, Inc.

Health CareBiotechnology$2.1B

Nov4Fri

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Immunome, Inc. is a biotechnology company focused on developing innovative therapies for cancer and other diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of profitability, and investors will look for signs of improvement or continued losses.

N/A

Revenue Growth

Revenue figures will indicate how well the company's products are performing in the market, which is essential for future growth.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

IMNM Q2-2026 Earnings Preview

Context

Company Snapshot

Immunome, Inc. is a biotechnology company focused on developing innovative therapies for cancer and other diseases. With a market cap of $2 billion, it operates in the health care sector, which is increasingly important as advancements in biotechnology continue to shape treatment options.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-68.16%

Avg Stock Reaction

-1.95%

Last Quarter Recap

In the last quarter, Immunome reported an EPS of -$0.48, which was better than the expected -$0.60, resulting in a positive surprise. However, the stock still declined by 1.35% the following day, reflecting market skepticism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for this quarter are uncertain as there are no analyst estimates available. Investors will be keenly watching for any signs of improvement in profitability and revenue.

Bull Case

If Immunome shows a significant reduction in losses and improved revenue growth, it could signal a turnaround, attracting more investor interest.

Bear Case

Conversely, if the company continues to report larger-than-expected losses without clear revenue growth, it may lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Immunome provide any guidance on revenue growth or new product developments?

Clear guidance could help investors gauge the company's future prospects and potentially stabilize the stock price.

What are the company's plans to reduce losses in the upcoming quarters?

Investors will be looking for concrete steps to improve profitability, as continued losses could lead to negative sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for Immunome to improve its financial performance, as historical trends show that the company has occasionally surprised on the upside.

Supporting Evidence

The options market is pricing a 44.33% move, indicating expectations of volatility that may not align with historical performance.

Immunome has shown a pattern of beating EPS estimates, which could indicate potential for positive surprises.

The stock has previously reacted positively to smaller beats, suggesting that even minor improvements could lead to significant price movements.

Key Risk

If the company can demonstrate a clear path to reducing losses or improving revenue, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Immunome can demonstrate a path to profitability amidst ongoing losses.

Bull Confirmed If

A reduction in EPS losses to below -$0.40 would confirm the bull case.

Bear Confirmed If

If EPS losses exceed -$0.50, it would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±44.33%

Historical Avg

±3.8%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect considerable volatility around the earnings announcement.

Options are pricing ±44.3% while IMNM has averaged ±3.8% over the last 8 prints — setup is pricing rich.

Detail

30d HV

54.2%

Calls (11K)P/C Ratio: 5.31Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Immunome beats expectations and raises guidance, history suggests a potential stock increase of around 0.5% on the first day.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see muted movement.

Miss

If the company misses expectations, history suggests a potential decline of around 3.42% on the first day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline developments and their expected timelines.
2Details on cost management strategies to reduce losses.
3Insights into market demand for Immunome's therapies.
4Any partnerships or collaborations that could enhance growth prospects.
5Management's outlook on the competitive landscape in the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Cirrus Logic, Inc.

Company Snapshot

Immunome, Inc. is a biotechnology company focused on developing innovative therapies for cancer and other diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of profitability, and investors will look for signs of improvement or continued losses.

N/A

Revenue Growth

Revenue figures will indicate how well the company's products are performing in the market, which is essential for future growth.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

IMNM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-68.16%

Avg Stock Reaction

-1.95%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for this quarter are uncertain as there are no analyst estimates available. Investors will be keenly watching for any signs of improvement in profitability and revenue.

Bull Case

If Immunome shows a significant reduction in losses and improved revenue growth, it could signal a turnaround, attracting more investor interest.

Bear Case

Conversely, if the company continues to report larger-than-expected losses without clear revenue growth, it may lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Immunome provide any guidance on revenue growth or new product developments?

Clear guidance could help investors gauge the company's future prospects and potentially stabilize the stock price.

What are the company's plans to reduce losses in the upcoming quarters?

Investors will be looking for concrete steps to improve profitability, as continued losses could lead to negative sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for Immunome to improve its financial performance, as historical trends show that the company has occasionally surprised on the upside.

Supporting Evidence

The options market is pricing a 44.33% move, indicating expectations of volatility that may not align with historical performance.

Immunome has shown a pattern of beating EPS estimates, which could indicate potential for positive surprises.

The stock has previously reacted positively to smaller beats, suggesting that even minor improvements could lead to significant price movements.

Key Risk

If the company can demonstrate a clear path to reducing losses or improving revenue, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Immunome can demonstrate a path to profitability amidst ongoing losses.

Bull Confirmed If

A reduction in EPS losses to below -$0.40 would confirm the bull case.

Bear Confirmed If

If EPS losses exceed -$0.50, it would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±44.33%

Historical Avg

±3.8%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect considerable volatility around the earnings announcement.

Options are pricing ±44.3% while IMNM has averaged ±3.8% over the last 8 prints — setup is pricing rich.

Detail

30d HV

54.2%

Calls (11K)P/C Ratio: 5.31Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Immunome beats expectations and raises guidance, history suggests a potential stock increase of around 0.5% on the first day.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see muted movement.

Miss

If the company misses expectations, history suggests a potential decline of around 3.42% on the first day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline developments and their expected timelines.
2Details on cost management strategies to reduce losses.
3Insights into market demand for Immunome's therapies.
4Any partnerships or collaborations that could enhance growth prospects.
5Management's outlook on the competitive landscape in the biotechnology sector.